



Your Elrexfio® ▼ (elranatamab) Patient Alert Card

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Elranatamab is used to treat adults with a type of cancer of the bone marrow called multiple myeloma. It is used on its own for patients whose cancer has returned (relapsed) and stopped responding to previous treatments (refractory), who have had at least three other kinds of treatment and whose cancer has progressed since receiving the last treatment.

You should remain within proximity of a healthcare facility, and be monitored for signs and symptoms daily for 48 hours after administration of the first 2 step-up doses of elranatamab.

**ALWAYS CARRY
THIS CARD WITH YOU. SHOW
THIS CARD to any healthcare professional
involved in your care and if you go to the
hospital, including the Accident & Emergency Unit.**



IMPORTANT SAFETY INFORMATION FOR PATIENTS RECEIVING TREATMENT

Elranatamab can cause Cytokine Release Syndrome (CRS), and neurologic toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS), which may be fatal or life threatening.

Symptoms of CRS and ICANS can include but are not limited to fever, hypoxia and chills. Call your doctor, pharmacist or nurse to get emergency help if you experience any of these side effects:

- Fever (38°C or higher)
- Chills
- Shortness of breath
- Fast heartbeat
- Headache
- Dizziness or light-headedness
- Feeling confused, less alert and difficulty speaking or writing
- Tremor
- Limb weakness
- Seizures
- Nausea
- Diarrhoea
- Reduced appetite
- Rash

**Please review the Patient Information Leaflet (PIL)
for a full list of side effects related to elranatamab.**

REMEMBER: If you have **any** of the side effects listed below, call your doctor or seek emergency medical attention right away! These are not all of the possible side effects of elranatamab. Tell your doctor, nurse or pharmacist if you experience any side effects.

Please talk to your doctor, nurse or pharmacist if you have any questions about the information in this card.

Patient name:

has received elranatamab.

Name of treating oncologist:

Office phone:

After hours phone:



Dates of elranatamab injections:

- Step-up dose 1: _____
- Step-up dose 2: _____
- First full dose: _____

Reporting of Side Effects:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.